NCT06045091View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Multiple MyelomaPlasma Cell Leukemia
Interventions
DRUG

Human BCMA targeted CAR-NK cells injection

Allogenic genetically modified anti-BCMA CAR transduced NK cells

Trial Locations (1)

200003

RECRUITING

Shanghai Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY